Sex: M
Vaccine: COVID19
Symptoms: Glomerular filtration rate, Glomerulonephritis membranous, Protein urine present
Clinical narrative: This spontaneous report was received from literature. This report concerned a 68 year old male. This study identified 29 patients with glomerular disease development in close temporal association with SARS CoV-2 immunization. The patient's height, and weight were not reported. The patient's concurrent conditions included: chronic kidney disease (Glomerular Filtration Rate (GFR), 60 mL/min). The patient had no prior COVID-19. The patient received Covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: unknown, expiry: unknown) dose, start therapy date were not reported, 1 total for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On an unspecified date, less than four weeks of vaccination, patient experienced symptoms as Acute Kidney Injury (AKI), nephritic syndrome and diagnosed as membranous nephropathy. Laboratory data (dates unspecified) included: Antineutrophil Cytoplasmic Antibodies (ANCA) (NR: not provided) Negative, Albumin (NR: not provided) 3.2 (units unspecified), Creatinine (NR: not provided) 3.3 (units unspecified), Blood in urine (Hematuria) (NR: not provided) Negative, Protein urine present (Proteinuria) (NR: not provided) 0.6 (units unspecified). Kidney biopsy showed membranous nephropathy (Global Glomerulosclerosis: 20/29, No Mesangial Matrix Expansion, No Mesangial Hypercellularity, No Endocapillary Hypercellularity. No Necrosis, No Crescents, Segmental Sclerosis, Acute Tubular Injury, Mild Interstitial Fibrosis/Tubular Atrophy, Severe Arteriosclerosis, No Arteriolar Hyalinosis, Immunofluorescence (2+IgG, 2+IgM gr cap loop), No Mesangial Deposits, No Subendothelial Deposits, Subepithelial Deposits, Severe Foot Process Effacement). On follow up Laboratory data (dates unspecified) included: Creatinine (NR: not provided) 2.74 (units unspecified), Protein urine present (Proteinuria) (NR: not provided) 0.38 (units unspecified). Prior to biopsy and after biopsy, the patient was on treatment with diuretics. The patient had partial recovery, with a reduction in serum creatinine but with persistent hematuria and/or proteinuria. The action taken with Covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from membranous nephropathy. The authors concluded that further data was required to determine the incidence of glomerular disease induction or recurrence in response to vaccination, response to therapy, and long-term clinical outcomes. Authors suggested that new onset or recurrent glomerular disease should be monitored as a potential adverse event. This report was serious (Other Medically Important Condition). This case, from Same Literature article is linked to 20210803054. Sender's Comments: V0: 20220410382-Covid-19 vaccine ad26.cov2.s- MEMBRANOUS NEPHROPATHY. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s). Therefore, this event(s) is considered unassessable.